Fitness Costs of Mutations at the HIV-1 Capsid Hexamerization Interface

Sririphan Manocheewa, J. Victor Swain, Erinn Lanxon-Cookson, Morgane Rolland*, James I. Mullins*

Department of Microbiology, University of Washington, Seattle, Washington, United States of America

Abstract

The recently available x-ray crystal structure of HIV-1 capsid hexamers has provided insight into the molecular interactions crucial for the virus’s mature capsid formation. Amino acid changes at these interaction points are likely to have a strong impact on capsid functionality and, hence, viral infectivity and replication fitness. To test this hypothesis, we introduced the most frequently observed single amino acid substitution at 30 sites: 12 at the capsid hexamerization interface and 18 at non-interface sites. Mutations at the interface sites were more likely to be lethal (Fisher’s exact test p = 0.027) and had greater negative impact on viral replication fitness (Wilcoxon rank sum test p = 0.040). Among the interface mutations studied, those located in the cluster of hydrophobic contacts at NTD-NTD interface and those that disrupted NTD-CTD interdomain helix capping hydrogen bonds were the most detrimental, indicating that these interactions are particularly important for maintaining capsid structure and/or function. These functionally constrained sites provide potential targets for novel HIV drug development and vaccine immunogen design.

Citation: Manocheewa S, Swain JV, Lanxon-Cookson E, Rolland M, Mullins JI (2013) Fitness Costs of Mutations at the HIV-1 Capsid Hexamerization Interface. PLoS ONE 8(6): e66065. doi:10.1371/journal.pone.0066065

Editor: January D. Barbour, University of Hawaii Manoa, United States of America

Received May 3, 2013; Accepted June 13, 2013; Published June 13, 2013

Copyright: © 2013 Manocheewa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from the U.S. Public Health Service to JIM (AI47734 and AI57005), the University of Washington Center for AIDS Research Computational Biology Core (AI27757), and the Bill and Melinda Gates Foundation (43437). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: jmullins@uw.edu

Introduction

Human immunodeficiency virus type 1 (HIV-1) is an enveloped retrovirus with a protein shell, or capsid, enclosing the viral genome and its associated enzymes. The immature capsid is formed inside a host cell as a spherical shaped particle made up of Gag polyproteins. Upon budding and release from the host cell, the Gag polyproteins are cleaved by the viral protease, resulting in separation of CA from other functional domains of Gag. The CA units then rearrange to form a more condensed, cone-shaped mature capsid. This process is called maturation [1] and is necessary for successful production of infectious virions. The mature HIV-1 capsid is organized like a fullerenic cone, and is made up of approximately 250 hexamer and 12 pentamer units of CA [2,3]. Each CA protein consists of two independently folded domains – the amino-terminal domain (NTD) and the carboxy-terminal domain (CTD). The two domains are joined by a short unfolded region called the flexible linker [4]. A recently solved high-resolution crystal structure of the capsid hexamer revealed two main interfaces between CA subunits within the hexamer – the NTD-NTD and NTD-CTD interfaces [5].

Amino acid changes at these interface sites have the potential to impair CA-CA interactions and hence destabilize the hexamer structure. Such mutations would also be expected to have a negative impact on viral replication, as previous studies showed that mutations that affected capsid morphology and stability also abolished viral infectivity [6–9]. Indeed, some mutations at several interface sites were shown to result in less- or in some cases, non-infectious virus, while others did not have the same negative effects, suggesting that side-chain interactions had different effects on viral infectivity [7].

Identification of critical residues or side-chain interactions may facilitate the development of novel anti-HIV therapies targeting the capsid [10], including immunogens for cytotoxic T lymphocyte (CTL) based HIV vaccines. CTL responses are crucial for control of viral replication during infection [11,12]. However, while CTL responses are extensive, their effectiveness is mitigated by immune escape mutations, which allow the virus to evade immune responses and continue to replicate [13,14]. Focusing immune responses on the functionally constrained regions of the viral proteome can potentially alleviate this problem, as immune escape mutations may be expected to impair viral replication and reduce viral spread [15,16]. This information would also be useful for development of novel anti-HIV drugs targeting the capsid [10].

A structural characterization of the CA-CA interface within capsid hexameric units was presented in 2009 [5], but the effects of mutations at many of these interface sites have not been investigated. Importantly, most of the previous work utilized alanine-scanning mutagenesis or other non-conservative amino acid changes to study alterations in CA production, capsid formation and viral infectivity. While such approaches are suitable for studying a functional or structural role of specific residues within a protein or protein complex, they did not take into account the likelihood of the observed mutations at a given residue during HIV evolution. Such information is useful when considering potential sites for drug target or vaccine immunogens and plausible drug/immune escape mutations. To gain such informa-
tion, we introduced the most frequently observed mutation in natural infections at 12 interface sites and 18 non-interface sites and studied their impact on viral fitness. Our results showed that commonly observed mutations at interface sites were more likely to have deleterious effects on viral replication than mutations at non-interface sites. These results support the potential of CA-CA interfaces as drug targets and for inclusion of these sites in vaccine immunogens.

Materials and Methods

Mutation Sites

The capsid hexamerization interface site is defined as any amino acid residue that forms at least one non-bonded contact with a residue from another CA subunit within the same capsid hexamer. The number and type of non-bonded contacts was determined, as part of the COTM Gag sequence, based on the phylogenetic tree and the COTM CA sequence were prepared using the MUSCLE program and then manually edited with 1 ug of the chimeric plasmid using the FuGENE6 DNA transfection reagent (Roche). Cell-free supernatants were harvest-48 hours post-transfection, filtered through a 0.22 um filter, and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruplicate as the 50% tissue culture infectious dose (TCID50) and stored in 250 ul aliquots at -80C until use. p24 production in transfection supernatants was determined using an in-house antigen [21]. The viral titer for each stock was calculated in quadruple...
0.5 ml of the culture supernatant was removed and replaced with warm complete RPMI-1640. Cultures were spun for 5’ at 228 xg, and then 0.75 ml of the culture supernatant was again replaced. On days 0, 3, 5, 7 and 9, 0.5 ml of culture supernatant was replaced and the removed supernatant transferred to a sterile 1.0 ml microcentrifuge tube. Supernatants were centrifuged for 5’ at 228 xg and cell free fluids were stored at −80°C in 200 ul aliquots.

**Viral growth (mono-infection) assay.** Viral-cell cultures were set up as described above using an MOI of 0.005. For repeated analysis of mutants with undetectable infectious titer, 0.5 ml of viral stock was used as inoculum.

**Nucleic acid preparation and amplification.** Viral RNA was extracted from 200 ul cell-free supernatants by an ion exchange membrane technology on a QIAextractor robot following the manufacturer’s protocol (Qiagen). RNA was stored at −80°C prior to cDNA synthesis. One 25 ul cDNA synthesis reaction consisted of master mix 1 (final concentration: 0.5 mM dNTPs, 0.5 uM RT-2 primer), master mix 2 (final concentration: 1X first strand buffer, 0.005 M DTT, 10/u ul Superscript III reverse transcriptase (Invitrogen), 2/u ul RNase Inhibitor (Invitrogen), and 10 uM RNA. Four ul of master mix 1 was transferred to each reaction well in a 96 well PCR plate. Ten ul of RNA was added to each reaction well and incubated at 60°C for 5 min. The reaction was then held at 4°C until master mix 2 was prepared. Ten ul of master mix 2 was added to each reaction well and the mixture incubated for 90 minutes at 50°C. Reverse transcriptase was inactivated by incubating the reaction for 15 minutes at 70°C and the reaction was then held at 4°C until real-time PCR quantitation.

**Real-time quantitative PCR (qPCR).** Viral RNA was quantified to determine the growth kinetics of each virus. All mutant viruses were generated using pNL4-3 with a vif tag (vifB) and were competed against the vifA reference virus. Viral RNA from the two viral strains was distinguished based on the presence or the absence of the vif tag mutations [23]. Real-time qPCR was done using an ABI 7300 Real-Time PCR System (Life Technologies), One 25 ul PCR reaction contained 12.5 ul TaqMan® Gene Expression Master Mix (Life Technologies), 5 uM probe, 20 uM of the forward and reverse primers [24], and 1 ul of cDNA. PCR cycling parameters were 50°C for 2 min, 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min. A standard curve was generated using pNL4-3 diluted serially from 3x10^5 to 300 copies/ul run in triplicate wells. The copy number of the forward and reverse primers [24], and 1 ul of cDNA. PCR cycling parameters were 50°C for 2 min, 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min. A standard curve was generated using pNL4-3 diluted serially from 3x10^5 to 300 copies/ul run in triplicate wells. The copy number of the forward and reverse primers [24], and 1 ul of cDNA. PCR cycling parameters were 50°C for 2 min, 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min. A standard curve was generated using pNL4-3 diluted serially from 3x10^5 to 300 copies/ul run in triplicate wells. The copy number of each sample. Each sample was run in duplicate wells.

**Estimating relative fitness.** All relative fitness estimations were done using the vFitness web tool [25]. The death rate of prototype and mutant viruses were set at 0.5. The least squares method was used to estimate fitness parameters from multiple data points. Data from the time points within the exponential growth phase were used for the relative fitness (1+ε) calculation [26]. Thus, the viral cDNA copy number measurements from day 2 and 5 samples were used when the COTM virus was competed against the NL4-3, while the copy number from day 3, 5 and 7 were used for competitions between COTM vifA and the COTM vifB mutants.

**Results**

**Chimeric HIV-1 COTM-CA Viruses**

The COTM-gag sequence was computationally derived to represent the central point of group M viral sequence diversity [19,27]. 1,019 full-length gag sequences, representing all group-M HIV-1 subtypes and circulating recombinant forms (CRFs), were obtained from the HIVDB; ~40% of the sequences were subtype B, and ~40% were subtype C; all other subtypes together comprised ~10%, and the remaining 10% corresponded to CRFs (Table S2). As the COTM sequence differed from known natural isolates or lab strains, we first confirmed that both COTM-CA-vifA and COTM-CA-vifB viruses were infectious in the CEMx174 T-cell line. We then competed the COTM-CA-vifA against the COTM-CA-vifB virus and showed that the six synonymous mutations in vif did not have an impact on viral replication fitness (Figure 1A). The COTM-CA-vifA virus was also competed against the NL4-3 virus, and was found to have a slower growth rate and hence lower relative fitness than the highly cultured adapted NL4-3 (Figure 1A and 1B).

**Mutations and CA Sequence Conservation**

The amino acid frequency at each site within CA was determined from the 1,019 codon-aligned sequences. CA sequences were relatively conserved across group M, with an average database frequency of the prototype amino acid of 0.94. Overall, capsid hexamerization interface sites were as conserved as other sites (Wilcoxon rank sum test p = 0.4317). However, when restricted to the sites included in this study, the interface sites tended to be slightly more conserved than non-interface sites but the difference did not reach statistical significance (Wilcoxon rank sum test p = 0.072) (Table S3).

Base on database frequency, the 30 amino acid sites included in this study can be categorized into three groups: 1) 18 sites whose mutation pattern was conserved across group M subtypes; 2) 2 sites whose subtype B mutation pattern is the opposite of subtype C; and 3) 4 sites whose mutation pattern in subtype B and subtype C are similar but different from that of other group M subtypes (Table S5). At all 30 sites, the most frequently found amino acid mutation was changed to the second most frequently observed one. In addition, alanine mutations were introduced at two interface sites, T186 and F301.

**Impact of Single Amino Acid Changes on COTM-CA Viral Replication**

Thirty-two COTM-CA-vifA mutants were generated. CA production was detected in all culture transfected with mutant plasmids. Transfection with four mutant plasmids (T58I, D166G, F161S, and T200S) yielded 20 fold or lower levels of CA production when compared to the prototype plasmid (Figure S2). From each viral stock, viral RNA was extracted, DNase treated and sequenced to confirm that no spurious mutation arose during the transfection process. The infectious titer of each viral stock was then determined (Figure 2A). Eleven of these mutants did not show detectable cytopathogenic effects (CPE) or CA production in TCID_{50} assays, in contrast to the prototypes and the other twenty-one mutants, suggesting that these mutants could not replicate at detectable levels in CEMx174. We also infected 10^5 CEMx174 cells with 0.5 ml of mutant viral stocks from the apparently defective mutants, along with 500 infectious units (IU) of COTM-CA-vifB and measured the amount of viral RNA from the culture supernatant on day 0, 3, 5, 7 and 9. For all eleven mutants, no growth was detected, although the mutant viral RNA remained above detectable levels (Figure 2B). Although we cannot completely rule out the possibility of the mutants replicating at very low levels, the mutant viral RNA detected is likely to be residual from the viral RNA in the inoculum at these levels steadily declined throughout the culture period (Figure 2B). Four out of these eleven non-infectious mutants also showed the lowest CA production in the 293T-transfected culture (Figure S2).
Mutations may interfere with the CA expression and/or the release of viral particle from host cell.

Next, we assessed the relative fitness of each of the other twenty-one mutants by competing them against the prototype COTM-CA-vifB virus in dual growth competition assays. At each time...
point, the mutant and the prototype viral RNA were quantitated using specific primer-probe set for vifA and vifB sequence respectively. Viral replication fitness was calculated based on the change in prototype and mutant viral ratio over time (Figure S1). The mean relative fitness (1+s) of these mutants was spread over a wide range, from 0.21 to 1.31 (Table 1). The majority of the mutations resulted in decreased replication fitness, with 5: A64G (mean 1+s = 0.21), V11I (0.24) D71E (0.25), E128D (0.30), and I124V (0.37), having the largest fitness costs (Figure 3A). These five mutants exhibited a longer lag phase of viral production in competition experiments and slower growth kinetics (Figure 3B).

Eight mutations: K203R, T216S, F169Y, V230I, S44A, V148T, M68I and I27V, resulted in varying but less severe fitness cost with mean 1+s ranges from 0.60 to 0.87. Three mutants: R154K, T110N, and R6I, also showed a trend of reduced fitness, although not significantly different from the prototype (95% CI p>0.05). Mutation I15L resulted in a trend toward higher replication fitness (95% CI p>0.05) while four mutants: T48A (mean 1+s = 1.12), G225S (1.21), E98D (1.28) and E45D (1.31), had a small but significantly faster growth rate than the prototype virus in all six replicates from two experiments (p<0.05) (Figure 3A and 3C).

**No Relationship between Sequence Conservation and Fitness Effects**

To examine the relationship between amino acid conservation and the mutational impact on viral fitness, the sites chosen for mutagenesis were differentially conserved, from a database frequency of 0.54 to 1.00 (Table 1). We found little direct relationship between the viral fitness and the database frequency of the prototype residue, with a non-significant Spearman’s correlation coefficient ρ = −0.27 (p = 0.136) and r² = 0.05 (p = 0.788) (Figure 4). This observation also held true without the inclusion of non-viable mutants (data not shown).

---

**Figure 3. Viral replication fitness and growth kinetics of COTM-CA mutants in pairwise competition assays.**

A) Relative fitness of the 21 viable mutants in CEMx174 cells. Values shown are an average from two experiments, with three replicates each. Error bars represent 95% confidence intervals. The dotted line represents neutral fitness. B) Growth kinetics of the five mutants (black lines) with substantial lower fitness compared to the COTM-CA prototype virus (gray lines). C) Growth kinetics of the four mutants with higher replication fitness than the prototype. Values shown are the average from one selected experiment done in triplicate. Error bar represents the standard deviation.

doi:10.1371/journal.pone.0066065.g003

---
Mutations at Interface Sites were more Likely to be Deleterious and had Higher Fitness Costs than Mutations at Non-interface Sites

Mutations at interface sites were significantly more likely to be lethal, with 8/14 mutants resulting in non-viable viruses compared to 3/18 non-interface mutants (Fisher’s exact test p = 0.027) (Figure 5A and Table 1). In addition, mutations at interface sites had significantly greater negative impact on viral fitness among the viable mutant viruses studied (Wilcoxon rank sum test p = 0.040) (Figure 5B and Table 1). Among the fourteen interface mutations, seven were in NTD-NTD and NTD-CTD interfaces (Table 1). Mutations at either interface were not significantly different in the generation of non-viable (Fisher’s exact test p = 0.30) or less fit mutants (Student’s t-test p = 0.32). For the NTD-NTD interface, five mutations (L20I, A42D, T54M, T54A and T58I) were located in a small patch of hydrophobic contacts between helix 1, 2 and 3, and two mutations (L6I and V11l) were situated in the beta strand at the beginning of the NTD. All five mutations in helix bundles resulted in non-viable viruses. On the other hand, both mutations in the beta strand resulted in viable viruses with L6I having a small (mean $1s = 0.85$) and V11l having a substantial ($1s = 0.24$) negative impact on viral fitness (Figure 6A). For the NTD-CTD interface, four mutations (A64G, M68I, F169Y and F169A) were situated in a cluster of hydrophobic contacts between helix 4, 8 and 11 and had various impacts on viral replication, from minor decreases to lethality (Figure 6A). The other three mutations were at sites forming inter-domain helix-capping motifs for helix 3, 4 and 8. Two of these, R173K and D166G, resulted in a loss of side-chain atoms required for hydrogen bonding (Figure 6B), and

| Location | Mutation | Amino acid frequency | Log$_{10}$ TCID50 | Relative Fitness ($1s$)* |
|----------|----------|----------------------|-------------------|--------------------------|
|          | Prototype | Mutated              |                   |                          |
| NTD-NTD  | L6I      | 0.687 0.066          | 5.24              | 1.00                     |
|          | V11l     | 0.939 0.037          | 3.43              | 0.24                     |
|          | L20I     | 1.000 0.000          | Undetectable      | –                        |
|          | A42D     | 1.000 0.000          | Undetectable      | –                        |
|          | T54M     | 0.867 0.096          | Undetectable      | –                        |
|          | T54A     | 0.867 0.005          | Undetectable      | –                        |
|          | T58I     | 0.876 0.103          | Undetectable      | –                        |
| NTD-CTD  | A64G     | 0.999 0.001          | 3.07              | 0.21                     |
|          | M68l     | 0.981 0.013          | 3.9               | 0.85                     |
|          | D71E     | 0.554 0.439          | 3.43              | 0.25                     |
|          | D166G    | 0.998 0.002          | Undetectable      | –                        |
|          | F169l    | 0.538 0.456          | 4.89              | 0.64                     |
|          | F169A    | 0.538 0.000          | Undetectable      | –                        |
|          | R173K    | 0.999 0.001          | Undetectable      | –                        |
| Non-interface | H12Y | 0.984 0.013 | Undetectable | –                     |
|          | I15l     | 0.617 0.320          | 5.77              | 1.10                     |
|          | I27V     | 0.575 0.419          | 3.91              | 0.79                     |
|          | S44A     | 0.965 0.029          | 5.1               | 0.78                     |
|          | E45D     | 0.987 0.008          | 5.1               | 1.31                     |
|          | T48A     | 0.984 0.006          | 4.18              | 1.12                     |
|          | E98D     | 0.918 0.074          | 4.98              | 1.28                     |
|          | T110N    | 0.861 0.118          | 4.62              | 0.89                     |
|          | I124V    | 0.739 0.246          | 3.67              | 0.37                     |
|          | E128D    | 0.601 0.390          | 3.91              | 0.30                     |
|          | V148T    | 0.663 0.274          | 5.24              | 0.81                     |
|          | R154K    | 0.555 0.438          | 4.02              | 0.82                     |
|          | F1615    | 0.993 0.002          | Undetectable      | –                        |
|          | T200S    | 0.842 0.091          | Undetectable      | –                        |
|          | K203R    | 0.588 0.406          | 4.02              | 0.60                     |
|          | T2165    | 0.976 0.009          | 4.98              | 0.62                     |
|          | G225S    | 0.562 0.416          | 4.14              | 1.21                     |
|          | V230I    | 0.925 0.066          | 4.38              | 0.77                     |

*Values shown are the average from two experiments done in triplicate.

doi:10.1371/journal.pone.0066065.t001
yielded non-viable mutants (Figure 2), while the other, D71E, also had a substantial negative impact on viral fitness (Figure 3).

Discussion

We assessed the replication fitness cost of thirty-two single amino acid substitutions in the HIV-1 CA of the HIV-1 M group Center-of-Tree sequence. The COTM-CA sequence was derived from all group M viruses to represent the central point of viral sequence diversity. As such, the COTM-CA sequence is not identical to any natural isolate of HIV-1 but rather a coalescence of prototype amino acid from all subtypes, especially the two best studied, B and C. In pairwise competition assays, the chimeric NL4-3 COTM-CA virus showed slower growth kinetics than the prototype NL4-3, a highly cell culture adapted subtype B virus. The lower relative fitness of the recombinant NL4-3 COTM-CA virus may be due to less optimal interactions between COTM-CA and other NL4-3 viral proteins. Alternatively, by combining multiclad prototype residues, we might have disrupted subtype specific co-evolving residual pairs, and in doing so negatively impacted the CA structure and/or function and hence viral replication fitness. Arguing against this possibility, however, the COTM-CA sequence retains almost all subtype specific co-evolving residues that have been reported previously [28]. The only exception is at the residue 41 and 120 pairing, in which the COTM-CA sequence contains serine at both position 41 and 120 of CA. The mutation S41T, which recovers the naturally observed co-variation threonine at 41 and serine at 120 [29] (Table S4), did not show a significant impact on the prototype COTM virus replication fitness (data not shown). Thus, despite slower growth kinetics than the highly cell-line adapted NL4-3 virus, the COTM-CA virus was infectious and applicable as the prototype virus for studying the effect of mutations within CA on viral fitness.

From thirty-two single amino acid substitutions introduced into the COTM-CA virus, eleven were lethal and seventeen had fitness costs, while four appeared to yield faster replicating capacities. The majority of the lethal mutations were located in the interface between CA subunits within a capsid hexamer. X-ray crystallographic studies identified two interfaces between capsid hexamer subunits: NTD-NTD and NTD-CTD. Both interfaces consist of a small cluster of hydrophobic contacts and a more extensive network of water mediated hydrogen bonds [5]. In this study, the hydrophobic contacts at NTD-NTD were highly sensitive to change and even conservative amino acid substitutions were found to be deleterious. On the other hand, mutations at interface residues at the beginning of the NTD, which are outside of the hydrophobic clusters, showed less impact on viral replication. The same cluster of hydrophobic contacts at NTD-NTD is also observed in the x-ray crystal structure of HIV-1 capsid pentamer [29]. Previous studies showed that alanine mutagenesis and substitution of hydrophilic for hydrophobic residues in this otherwise hydrophobic cluster drastically reduced viral infectivity and, in some cases, altered mature capsid morphology but not particle production [6,7,9]. Taken together, this suggests that stabilization of capsid hexameric and pentameric subunits through this NTD-NTD hydrophobic cluster is crucial for the capsid function and, hence, essential for viral replication.

Mutations at hydrophobic residues at the NTD-CTD interface also negatively affected viral replication. However, these effects seemed to be smaller, as only the F169A mutation was lethal. The
crucial interactions within the NTD-CTD interface were the inter-domain helix capping hydrogen bonds, which have been speculated to act as pivotal points for allowing one domain to move relative to another [5]. A similar structural motif was observed in the capsid hexamer of Rous sarcoma virus [30]. These pivotal points were suggested to be responsible for generating the continuously curved surfaces observed across retroviral capsids [5]. Five inter-domain helix-capping interactions were observed in the crystal structure of the HIV-1 capsid hexamer, three of which were consistently observed while the other two were found only in some protomers [5]. Among the three consistently observed interactions, R173 and D166 were suggested to be the most critical amino acids, based on the HIV-1 and RSV capsid structures, respectively [5,30]. Our results support these observations, as the mutations that disrupted these hydrogen bonds, R173K and D166G, were lethal.

Non-interface mutations included in this study were significantly less likely to be lethal (Fisher’s exact test p = 0.027) (Figure 5A) and showed less negative effects on viral replication (Wilcoxon rank sum test p = 0.040). Nevertheless, three mutations (H12Y, F161S and T200S) resulted in non-infectious mutants and two others (E128D and I124V) had substantial negative impacts on viral fitness, suggesting that these residues are important for CA functions other than the mature capsid assembly. On the other hand, four mutations (T48A, G225S, E98D and E45D) had positive effects on viral fitness. It remains to be established how these mutations affect CA structure and function.

In addition to exploring the association between structural localization and relative fitness, we examined the relationship between relative fitness and sequence conservation and found a non-significant trend between these two properties. Although the number of sites was limited to thirty, which accounts for about one-seventh of CA, our observation should not be particularly affected by sampling. The lack of direct relationship between sequence conservation and the relative fitness was surprising but not entirely unexpected [31]. Sequence conservation is influenced by evolutionary constraints, such as structural and functional requirements, and selective pressures, such as host immune pressure, as well as random genetic drift. The results presented here reflect the immediate impact of mutations on viral replication in a permissive T cell line, which would reflect CA structural and functional constraints but not host-specific selective pressures. In addition, our study focused on characterizing the effect of single mutations and hence did not account for possible occurrences of compensatory mutations, which could be part of the reason why some of the lethal mutations we observed, T54M, T58I and T200S, were found in noticeable fractions (~10%) of the HIVDB. Interestingly, these mutations were more frequently observed in non-B and non-C subtypes (Table 1 and Table S5). It is possible that their hypothetical compensatory mutations are missing from

Figure 6. Structural localization of interface mutations. A) Two CA chains are shown as gray/black and green ribbons. The interface residues evaluated in this study are highlighted in bold and red-orange-yellow color. Other previously studied residues [7,8] are highlighted in cyan-blue-purple color. The fitness impact of mutations is represented by the color shade ranging from small (yellow/cyan), moderate (orange/blue) to lethal (red/purple). B) Prototype residues participating in inter-domain helix capping hydrogen bonds, represented by orange lines, are shown on left. The mutations that resulted in loss of hydrogen bonds are modeled and highlighted on the right.

doi:10.1371/journal.pone.0066065.g006
our recombinant COTM-CA virus. Besides these three mutations, the other eight lethal mutations were rare and observed in ~1% or lower fraction of the HIVDB across all group M viruses (Table 1 and Table S5). To assess the influence of genetic background on the fitness effect, we compared results between this study and the fitness results from a study done in subtype B virus ([31], including 19 overlapping mutations with 6 at capsid hexamerization interface sites). We found a significant positive relationship between fitness effects in the two studies ($r^2 = 0.544$, $p = 0.0003$; Spearman’s $Rho = 0.774$, $p = 9.605E–05$) (Figure S3). Although our results may be affected by the limited capability of the in vitro fitness assay to recapitulate evolutionary forces in vivo, it indicates that extrapolating the direct impact of mutations on viral replication capability from the sequence conservation alone can be inaccurate and that incorporation of structural and functional information is essential.

Our observation that mutations at interface sites were likely to have a large negative impact on viral replication is in agreement with previous studies [7,8] and indicate the importance of capsid hexamerization in viral replication. However, certain side-chain interactions, such as NTD-NTD hydrophobic contacts and NTD-CTD helix capping hydrogen bonds, were found to be more important than others in maintaining capsid hexamer structures. As such they represent vulnerable targets that can be exploited in drug development and also vaccine designs that seek to target epitopes encompassing conserved elements critical to viral function [15,16,32,33].

Supporting Information

Figure S1 Viral ratio in pair-wise growth competition assay. Values shown are the average taken from one representative experiment done in triplicate. The bar error represents the standard deviation between the triplicates (TIF).

Figure S2 CA production in transfected 293T culture supernatant. (TIF)

Figure S3 Positive relationship between fitness effects in two strains. (TIF)

Table S1 Primers used to create new restriction sites and CA mutations in pNL4-3 plasmid.

References

1. Ganser-Pornillos BK, Yeager M, Sundquist WI (2008) The structural biology of HIV assembly. Curr Opin Struct Biol 18: 203–217.
2. Ganser BK, Li S, Kishlao Y, Finch JT, Sundquist WI (1999) Assembly and analysis of conical models for the HIV-1 core. Science 283: 80–83.
3. Briggs JA, Wilk T, Welker R, Krausslich HG, Fuller SD (2003) Structural organization of authentic, mature HIV-1 virions and cores. EMBO J 22: 1707–1715.
4. Berthet-Colominas C, Monaco S, Novelli A, Sibai G, Mallet F, et al. (1999) Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab. EMBO J 18: 1124–1136.
5. Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua Y, Whithby FG, et al. (2009) X-ray structures of the hexameric building block of the HIV capsid. Cell 137: 1262–1292.
6. Forshey BM, von Schwedler U, Sundquist WI, Aiken C (2002) Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol 76: 5667–5677.
7. von Schwedler UK, Stray KM, Garrus JE, Sundquist WI (2003) Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol 77: 5439–5450.
8. Bartonova V, Igonet S, Sticht J, Glais B, Habermann A, et al. (2008) Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein. J Biol Chem 283: 32024–32033.
9. Tang S, Murakami T, Agresta BE, Campbell S, Freed EO, et al. (2001) Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J Virol 75: 9357–9366.
10. Bocanegra R, Rodriguez-Hurte A, Fuentes MA, Del Alamo M, Mateu MG (2012) Molecular recognition in the human immunodeficiency virus capsid and antiviral design. Virus Res.
11. Koup RA, Saffir JT, Cao Y, Andrews CA, McLeod G, et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68: 4650–4655.
12. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13: 46–53.
13. Liu Y, McNeil J, Cao J, Zhao H, Genowati I, et al. (2006) Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol 80: 9519–9529.
14. Allen TM, Aldfeld M, Geer SC, Kalife ET, Moore C, et al. (2005) Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 79: 13239–13249.

Table S2 Distribution of HIV-1 subtypes in the dataset used to calculate amino acid sequence conservation and derive the COTM sequence. (DOCX)

Table S3 Database frequency of the consensus amino acid of group M HIV-1 CA. (DOCX)

Table S4 Subtype B, subtype C and COTM-CA amino acid at the co-evolving residual pair. Taken from [28]. (DOCX)

Table S5 Amino acid database frequency of subtype B, subtype C and other group M sequences. Base on database frequency, the 30 amino acid sites included in this study can be categorized into three groups (identified by superscripts in “Mutation” column). The first group contains 18 sites, whose mutation pattern was conserved among group M subtypes, i.e., the most frequent and the second most frequent amino acid were the same in both Subtypes B and C. The second group consists of 8 sites, in which the most frequent and the second most frequent residue found in subtype B and subtype C were opposite. For example, at site 71, the most frequent and the second most frequent amino acid was glutamic acid (0.93) and aspartic acid (0.05), respectively, in subtype B sequences. But in subtype C sequences, it was aspartic acid (0.98) and then glutamic acid (0.01). The third group contains 4 mutations, whose mutation pattern in subtype B and subtype C are similar to each other but different from that of other group M subtypes. (DOCX)

Acknowledgments

The authors would like to thank Dr. Robert A. Smith for critical reading and editing of the manuscript.

Author Contributions

Conceived and designed the experiments: SM MR JIM. Performed the experiments: SM MR JIM. Analyzed the data: SM MR JIM. Wrote the paper: SM MR JIM.
15. Rolland M, Nickle DC, Mullins JI (2007) HIV-1 Group M Conserved Elements Vaccine. PLoS Pathogens 3: e157.
16. Mothe B, Llano A, Barrondo J, Zamarreno J, Schiaulini M, et al. (2012) CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS ONE 7: e29717.
17. Laskowski RA (2009) PDBsum new things. Nucleic Acids Res 37: D355–359.
18. Maddison WP, Maddison DR (2011) Mesquite: a modular system for evolutionary analysis, 2.75 ed.
19. Nickle DC, Jensen MA, Gottlieb GS, Shriner D, Learn GH, et al. (2003) Consensus and ancestral state HIV vaccines. Science 299: 1513–1518; author reply 1515–1518.
20. Deng W, Maust BS, Nickle DC, Learn GH, Liu Y, et al. (2010) DIVEIN: A Web Server to Analyze Phylogenies, Sequence Divergence, Diversity, and Informative Sites. Biotechniques 48: 405–408.
21. McClure J, van’t Wout AB, Tran T, Mittler JE (2007) Granulocyte-monocyte colony-stimulating factor upregulates HIV-1 replication in monocyte-derived macrophages cultured at low density. J Acquir Immune Defic Syndr 44: 254–261.
22. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493–497.
23. Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, et al. (2009) Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 5: e1000365.
24. Liu Y, Mullins JI, et al (2012) A sensitive real-time PCR based assay to estimate the impact of amino acid substitutions on the competitive replication fitness of human immunodeficiency virus type 1 in cell culture. Journal of Virological Methods: In Press.
25. Ma J, Dykes C, Wu T, Huang Y, Demeter L, et al. (2010) vFitness: a web-based computing tool for improving estimation of in vitro HIV-1 fitness experiments. BMC Bioinformatics 11: 261.
26. Wu H, Huang Y, Dykes C, Liu D, Ma J, et al. (2006) Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J Virol 80: 2380–2389.
27. Rolland M, Jensen MA, Nickle DC, Yan J, Learn GH, et al. (2007) Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins. J Virol 81: 8507–8514.
28. Carlson JM, Brunme ZL, Rousseau CM, Brunme CJ, Matthews P, et al. (2008) Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol 4: e1000223.
29. Pornillos O, Gansev-Pornillos BK, Yeager M (2011) Atomic-level modelling of the HIV capsid. Nature 469: 424–427.
30. Bailey GD, Hyun JK, Mitra AK, Kingston RL (2012) A structural model for the generation of continuous curvature on the surface of a retroviral capsid. J Mol Biol 417: 212–223.
31. Rolland M, Manochewa S, Swain JV, Laxton-Cookson EC, Kim M, et al. (2013) HIV-1 conserved elements vaccines: Relationship between sequence conservation and replicative capacity. J Virol.
32. Mothe B, Llano A, Barrondo J, Daniels M, Miranda C, et al. (2011) Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med 9: 208.
33. Niu L, Termin JI, Kanagavelu SK, Gupta S, Rolland MM, et al. (2011) Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes. Vaccine 29: 2110–2119.